九州通(600998.SH):子公司成爲瑞舒伐他汀鈣片上市許可持有人
格隆匯3月18日丨九州通(600998.SH)公佈,公司子公司北京京豐製藥集團有限公司(以下簡稱“京豐製藥”)於2025年3月17日收到國家藥品監督管理局覈準簽發的兩份《藥品補充申請批準通知書》,批準瑞舒伐他汀鈣片(10mg、5mg)的藥品上市許可持有人變更爲北京京豐製藥集團有限公司。
瑞舒伐他汀鈣片是一種用於治療原發性高膽固醇血癥和混合型血脂異常症的處方藥。其活性成分瑞舒伐他汀是一種選擇性、競爭性的HMG-CoA還原酶抑制劑,它的作用機制在於阻止肝臟內膽固醇的合成,從而降低血液中低密度脂蛋白膽固醇的水平,同時也能幫助提升高密度脂蛋白膽固醇水平,從而改善整體的血脂狀況,降低心血管疾病風險。該藥品爲國家醫保乙類、國家基藥品種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.